Loading viewer...
investor_presentation
Format: PDF investor_presentation
Intellia is Leading the Genome Editing Revolution Corporate Overview SEPTEMBER 2022 Bill, living with transthyretin amyloidosis, and his wife, Maura
Intellia is Leading the
Genome Editing Revolution
Bill, living with transthyretin amyloidosis, and his wife, Maura2
Intellia Therapeutics’ Legal Disclaimer
This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”, “we” or“our”) within themeaning ofthePrivate Securities Litigation Reform Act
of1995 .These forward- looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s beliefs andexpectations regarding :itsability tobuild
aworld -class genome editing toolbox todevelop anunsurpassed genome editing pipeline; thesafety, efficacy andadvancement ofourclinical programs forNTLA -2001 forthe
treatment oftransthyretin amyloidosis andNTLA -2002 forthetreatment ofhereditary angioedema (“HAE”) pursuant toitsclinical trialapplications (“CTA”) andinvestigational
new drug (“IND”) submissions, including theexpected timing ofdata releases, regulatory filings, andtheinitiation andcompletion ofclinical trials ;itsability tosuccessfully pivot
toanallogeneic version ofNTLA -5001 andtoadvance thisprogram, including theexpected timing ofdata releases andregulatory filings ;itsability toconsistently deliver high-
quality, readily available andpersistent allogeneic cellproducts ;theadvancement ofitsdevelopment candidates including NTLA -3001 forthetreatment ofalpha- 1antitrypsin
deficiency (“AATD”) -associated lung disease, NTLA -2003 forAATD -associated liver disease, andNTLA -6001 forCD30+ lymphomas ;theability togenerate data toinitiate
clinical trials andthetiming ofCTA andINDsubmissions ;theadvancement, expansion andacceleration ofitsCRISPR/Cas 9technology andrelated technologies, including
DNA writing, base editing, manufacturing anddelivery technologies, toadvance anddevelop additional candidates andtreatments ;theability tomaintain andexpand our
related intellectual property portfolio, andavoid oracquire rights tovalid intellectual property ofthird parties ;theability todemonstrate ourplatform’s modularity andreplicate or
apply results achieved inpreclinical studies, including those inourNTLA -2001, NTLA -2002, NTLA -5001, NTLA -2003 ,NTLA -3001 ,andNTLA -6001 programs, inanyfuture
studies, including human clinical trials ;theability tooptimize theimpact ofourcollaborations onourdevelopment programs, including, butnotlimited to,ourcollaboration with
Regeneron Pharmaceuticals, Inc.(“Regeneron”), including ourco-development programs forhemophilia Aandhemophilia B,with AvenCell Therapeutics, Inc.(“AvenCell ”)for
thedevelopment ofuniversal CAR- Tcelltherapies, with SparingVision SAS (“SparingVision ”)forthedevelopment ofophthalmic therapies, with Kyverna Therapeutics, Inc.
(“Kyverna”) forthedevelopment ofKYV- 201,andwithONK Therapeutics Ltd.(“ONK”) forthedevelopment ofengineered NKcelltherapies ;andthepotential timing andreceipt
offuture milestones and royalties, orprofits, asapplicable, based onourlicense, collaboration and, ifapplicable, co-development agreements with Regeneron, Novartis
Preview truncated — download the full document for the complete content.
investor_presentation
84 Pages
investor_presentation
111 Pages
Westlake